What is the clinical evidence from this study?

Study design: Observational. Population: Angiosarcoma (n=34). Intervention: Targeted massively parallel sequencing. Primary outcome: Proportion of tumors with MAPK pathway genetic alterations.

September 30, 2015OncotargetOpen Access

Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway

View Full Paper

Ask AI

Bookmark

Key result

Targeted massively parallel sequencing revealed that 53% of angiosarcomas harbored genetic alterations activating the MAPK pathway, highlighting a potential therapeutic target.

Population

34 angiosarcomas

Design

Cohort

Authors

RMRajmohan MuraliMemorial Sloan Kettering Cancer Center RCRaghu ChandramohanGuardant (United States)IMInga MöllerDüsseldorf University Hospital

Discussion

Member takes

Implication

Hypothesis-generating for MAPK inhibition in angiosarcoma; prospective trials needed before clinical adoption.

Study Design

Type

Observational (n=34)

Multicenter

Yes

Structured PICO

Population

34 patients (median age 69, 71% female) with primary, recurrent, or metastatic angiosarcomas whose tumor samples underwent targeted next-generation sequencing.

Exposure

Comprehensive genomic analysis using a clinically-approved, hybridization-based targeted next-generation sequencing assay for 341 well-established oncogenes and tumor suppressor genes

Outcome

Genetic alterationssurrogate

Angiosarcomas frequently harbor genetic alterations affecting the MAPK pathway, suggesting that targeted therapies inhibiting MAPK signaling may be promising therapeutic avenues.

Limitations

Detailed clinical data, including therapy and follow-up information, was not available.
The high heterogeneity of genetic alterations requires larger sample numbers with detailed clinical follow-up to meaningfully assess the clinical consequences of individual genetic alterations.

Cite This Study

Murali et al. (2015) conducted an observational in Angiosarcoma (n=34). Targeted massively parallel sequencing was evaluated on Proportion of tumors with MAPK pathway genetic alterations. Targeted massively parallel sequencing revealed that 53% of angiosarcomas harbored genetic alterations activating the MAPK pathway, highlighting a potential therapeutic target.

synapsesocial.com/papers/6a8714b0ddd5671cb07ccbb2 https://doi.org/10.18632/oncotarget.5936

View Full Paper

Ask AI

Bookmark

Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway

Discussion

Member takes

Implication

Study Design

Structured PICO

Limitations

Cite This Study

Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway

Discussion

Member takes

Implication

Study Design

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider